Novo Nordisk (NOVOB DC) and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
Importance
Level 1
- Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration, research funding and milestone payments totalling up to USD 2.1bln, and tiered royalties on future product sales.
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES